Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 117 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H2 2016', provides in depth analysis on Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted pipeline therapeutics. 

The report provides comprehensive information on the Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) 
- The report reviews Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) Overview 10
Therapeutics Development 11
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Products under Development by Stage of Development 11
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Products under Development by Therapy Area 12
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Products under Development by Indication 13
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Products Glance 15
Late Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Products under Development by Companies 18
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Products under Development by Universities/Institutes 21
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Therapeutics Assessment 23
Assessment by Monotherapy/Combination Products 23
Assessment by Mechanism of Action 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Companies Involved in Therapeutics Development 29
AFFiRiS AG 29
Betagenon AB 30
BioLingus AG 31
Catabasis Pharmaceuticals, Inc. 32
Daiichi Sankyo Company, Limited 33
Dicerna Pharmaceuticals, Inc. 34
Eli Lilly and Company 35
Ensemble Therapeutics Corporation 36
HitGen LTD 37
Kowa Company, Ltd. 38
Kymab Limited 39
MedImmune, LLC 40
Novartis AG 41
Pfizer Inc. 42
Planet Biotechnology Inc. 43
Regeneron Pharmaceuticals Inc 44
Serometrix, LLC 45
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 46
The Medicines Company 47
Thetis Pharmaceuticals LLC 48
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Drug Profiles 49
(atorvastatin calcium + TP-452) - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
alirocumab - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
ALN-PCSsc - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
Antisense Oligonucleotide to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
ATH-04 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
ATH-06 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
bococizumab - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
CAT-2000 Series - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
DCRPCSK-9 - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
DS-9001 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
Gene Therapy to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
JS-002 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
K-312 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
KY-1020 - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
lodelcizumab - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
LY-3015014 - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
MEDI-4166 - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
Monoclonal Antibodies to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
Monoclonal Antibody to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
O-304 - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
Recombinant Protein to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
Small Molecule to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
Small Molecule to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
Small Molecules to Inhibit PCSK9 for Acute Coronary Syndrome and Atherosclerosis - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
Small Molecules to Inhibit PCSK9 for Cardiovascular Disease - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
Small Molecules to Inhibit PCSK9 for Coronary Artery Disease and Metabolic Disorders - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
Small Molecules to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
SX-PCK9 - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
Synthetic Peptide to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
TP-452 - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
Vaccine to Target PCSK9 for Hypercholesterolemia - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Dormant Projects 97
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Discontinued Products 99
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Featured News & Press Releases 100
Oct 18, 2016: The Medicines Company Announces Positive Top-Line Results from Day 90 Interim Analysis in Ongoing ORION-1 Phase 2 Study of PCSK9si 100
Oct 05, 2016: The Medicines Company Provides Progress Update on Ongoing ORION-1 Study of PCSK9si 101
Aug 30, 2016: Betagenon: Start of Phase IIa Proof-of-Concept Clinical Trial of AMPK Activator O304 in Type 2 Diabetics 102
Aug 30, 2016: The Medicines Company Provides Update on PCSK9si (PCSK9 synthesis inhibitor) 102
Aug 29, 2016: Regeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016 103
Jul 05, 2016: Regeneron and Sanofi Announce Approval of Praluent (alirocumab) for the Treatment of Hypercholesterolemia in Japan 104
Jun 28, 2016: Two Additional Phase 3 Lipid-Lowering Studies of Bococizumab Deliver Positive Topline Results 105
Jun 22, 2016: NICE Green Lights Cholesterol-Lowering Treatment Praluent (alirocumab) For NHS Funding 107
Jun 02, 2016: The Medicines Company Completes Patient Enrollment for ORION-1 Study of PCSK9si 108
May 24, 2016: New Cholesterol Treatment Now Available for Canadians 109
May 16, 2016: ICON and Pfizer Honoured as Clinical Research Team of the Year at the Clinical and Research Excellence Awards 110
May 11, 2016: Cigna's New Value-Based Contract with Sanofi/Regeneron for Praluent 111
May 06, 2016: Innovative cholesterol-lowering treatment, Praluent (alirocumab), approved by NICE for people with raised cholesterol levels who are at significantly high risk of a heart attack or stroke 112
Apr 26, 2016: Bococizumab SPIRE-2 Cardiovascular Outcome Study Fully Enrolled 113
Apr 01, 2016: Pfizer Announces Positive Topline Results From Second Phase 3 Lipid-Lowering Study Evaluating Bococizumab 114
Appendix 116
Methodology 116
Coverage 116
Secondary Research 116
Primary Research 116
Expert Panel Validation 116
Contact Us 116
Disclaimer 117

List of Tables

Number of Products under Development for, H2 2016 11
Number of Products under Development by Therapy Area, H2 2016 12
Number of Products under Development by Indication, H2 2016 14
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Early Stage Products, H2 2016 16
Comparative Analysis by Unknown Stage Development, H2 2016 17
Number of Products under Development by Companies, H2 2016 18
Products under Development by Companies, H2 2016 19
Products under Development by Companies, H2 2016 (Contd..1) 20
Number of Products under Investigation by Universities/Institutes, H2 2016 21
Products under Investigation by Universities/Institutes, H2 2016 22
Assessment by Monotherapy/Combination Products, H2 2016 23
Number of Products by Stage and Mechanism of Action, H2 2016 24
Number of Products by Stage and Route of Administration, H2 2016 26
Number of Products by Stage and Molecule Type, H2 2016 28
Pipeline by AFFiRiS AG, H2 2016 29
Pipeline by Betagenon AB, H2 2016 30
Pipeline by BioLingus AG, H2 2016 31
Pipeline by Catabasis Pharmaceuticals, Inc., H2 2016 32
Pipeline by Daiichi Sankyo Company, Limited, H2 2016 33
Pipeline by Dicerna Pharmaceuticals, Inc., H2 2016 34
Pipeline by Eli Lilly and Company, H2 2016 35
Pipeline by Ensemble Therapeutics Corporation, H2 2016 36
Pipeline by HitGen LTD, H2 2016 37
Pipeline by Kowa Company, Ltd., H2 2016 38
Pipeline by Kymab Limited, H2 2016 39
Pipeline by MedImmune, LLC, H2 2016 40
Pipeline by Novartis AG, H2 2016 41
Pipeline by Pfizer Inc., H2 2016 42
Pipeline by Planet Biotechnology Inc., H2 2016 43
Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 44
Pipeline by Serometrix, LLC, H2 2016 45
Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H2 2016 46
Pipeline by The Medicines Company, H2 2016 47
Pipeline by Thetis Pharmaceuticals LLC, H2 2016 48
Dormant Projects, H2 2016 97
Dormant Projects (Contd..1), H2 2016 98
Discontinued Products, H2 2016 99